Viridian Therapeutics, Inc.

1. 01

   Ahead of SPY, behind its sector fund XLV over 1 year

   1 month: +59.5% (SPY −1.6%, XLV +13.5%). 3 months: +37.9% (SPY −0.4%, XLV +15.5%). 1 year: +28.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: VRDN, SPY and XLV · as of 4 Nov 2026

2. 02

   Volume 5.2× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 11.2M shares was 5.2× the average of the 30 sessions before it (2.2M), as the price rose 15.5%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

3. 03

   Above its 50- and 200-day averages

   The 4 Nov 2026 close of $29.06 was 33.3% above its 50-day average ($21.80) and 34.2% above its 200-day average ($21.66). It has closed above the 200-day for 12 sessions, since 20 Oct 2026. The 50-day average crossed above the 200-day on 3 Nov 2026, 1 session ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

4. 04

   8.0 days to cover short interest

   18.0M shares were sold short at the 15 Oct 2026 settlement, 15.9% of the 113.3M shares outstanding; covering them would take 8.0 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

5. 05

   Rose 15.5% on 4 Nov 2026

   The 4 Nov 2026 gain of 15.5% was 6.0× its average daily move of 2.6% over the past year, and its largest one-day gain since 5 May 2026.

   Daily closes, split-adjusted · as of 4 Nov 2026

At the 4 Nov 2026 close